Industrialized Production of Human iPSC-Derived Cardiomyocytes for Use in Drug Discovery and Toxicity Testing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industrialized Production of Human iPSC-Derived Cardiomyocytes for Use in Drug Discovery and Toxicity Testing
The authors describe an industrialized process for the manufacture of iPSC-derived human cardiomyocytes. This article is part of a special issue on Bioprocessing and Sterile Manufacturing.


Pharmaceutical Technology
Volume 34, pp. s8-s15


CELLULAR DYNAMICS INTERNATIONAL
Drug toxicity that emerges either in late-stage clinical trials or following market launch has been a long-term problem for the pharmaceutical industry. The fundamential challenge is that existing preclinical models do not adequately predict the toxicity of new chemical entities. Current cell models are either primary cell cultures derived from non-human animals or immortal cell lines derived from tumors. Because of their non-human nature or neoplastic life history, they are imperfect predictors of drug toxicity in humans. Recent advances in stem-cell technology hold the potential to overcome such limitations.

The identification and isolation of stem cells from human embryos opened the promise of using human cells to more efficiently drive drug discovery and toxicity assessments (1). At some point, stem cells may also be used in regenerative medicine to repopulate or even replace diseased tissues and organs. Human embryonic stem cells (ESCs) can differentiate into any of the 200-plus cell types found in the human body.Unfortunately, human ESCs have their drawbacks. Because of their source, ethical controversy has surrounded ESC research since the cells were first isolated in 1998. Furthermore, as they are derived from surplus embryos from in vitro fertilization procedures, their sources and genetic make-up are unknown, thus limiting their utility for investigating potential compound toxicity in targeted human subpopulations.

Induced pluripotent stem cells (iPSCs), on the other hand, possess the advantages of ESCs, avoid the associated ethical implications, and have the intrinsic ability to be a more flexible cell-based research tool. iPSCs are produced from somatic cells that are induced to a pluripotent state by the incorporation of genetic and small-molecule factors that reprogram the somatic cell to a stem cell (2–4). iPSCs have the same pluripotent capabilities of ESCs and the advantages of originating from individuals with identifiable phenotypes and genotypes, thus enabling the use of targeted human subpopulation models early in drug discovery and toxicity screening.

Producing cardiomyocytes from human ESCs and iPSCs using the embryoid body (EB) and directed differentiation methods is well documented (5, 6). The efficiency with which these methods can differentiate ESCs and IPSCs into cardiomyocytes is highly variable, but consistent among both methods is a difficulty in producing highly pure (> 90%) populations of cardiomyocytes. Additional comparisons of cardiomyocyte generation from human ESCs and iPSCs suggest that both starting materials have an equivalent cardiogenic capacity (7), and further molecular and electrophysiological analyses demonstrate that both starting materials produce differentiated cardiomyocytes with phenotypes consistent with atrial, ventricular, and nodal cardiomyocyte subtypes (5, 6).

As described above, human iPSCs have particular advantages over ESCs for drug discovery and toxicity testing when induced to differentiate into a mature cell type. The significant challenge for commercialization of such cells is the ability to consistently produce both starting material iPSCs and the differentiated cells in the quantity, quality, and purity required by the pharmaceutical industry. Here we will describe a process by which we have industrialized the manufacture of iPSC-derived human cardiomyocytes. This process, as currently practiced at Cellular Dynamics International (CDI), is capable of meeting the foreseeable demand for purified iPSC-derived human cardiomyocytes and is scalable by more than two orders of magnitude if necessary without difficulty. We will illustrate the purification process and show that the human cardiomyocytes generated from this process express the same genes, proteins, electrophysiological properties, and responses to cytotoxic substances and ion channel blockers expected of cardiomyocytes.

Manufacture of human iPSCs

iPSCs are developed from human fibroblasts, skin, blood, or other somatic cell types collected from individuals. The purified somatic cells are exposed to reprogramming agents that stimulate de-differentiation into iPSCs. Typically, reprogramming somatic cells is a slow and complicated process to which many investigators have contributed different methodologies (8). Originally, the reprogramming process required genetic modification of the source material with viral vectors that permanently integrate into seemingly random locations within the host DNA. Although the reprogrammed cells exhibited the properties of stem cells, the integrated vectors limited the usefulness of the cells to clinical or drug testing applications because of the perceived potential mutagenic or oncogenic effects of the integrated DNA. New reprogramming methodologies have been developed that largely overcome this barrier (9, 10) so that reprogrammed cells do not have foreign DNA, vector or otherwise, integrated into the genome, thus creating iPSC lines with potential applications in clinical as well as discovery settings.


Figure 1 ALL FIGURES ARE COURTESY OF CELLULAR DYNAMICS INTERNATIONAL (CDI)
The key to the mass production of iPSCs is to develop a process that is both scalable and standardizable (see Figure 1). iPSCs, by their nature, are highly proliferative and have the potential to greatly expand their numbers under cell culture conditions. However, they are also very sensitive to manipulation and thus require special treatment and expertise to prevent entry into various non-directed differentiation pathways, events which greatly reduce the ability of the cell population to undergo directed differentiation and reduce the health of the relatively few terminally differentiated cells that are produced.

To prevent entry of iPSC populations cultured under standard conditions into non-directed differentiation pathways, such differentiated cells must be removed and "weeded out" of the population. This weeding step is subjective, labor-intensive, and highly dependent on the skill and attention of the technician. Therefore, to manufacture the necessary number of iPSCs needed to produce terminally differentiated cells for use by the pharmaceutical industry, we have simplified the process to enable standardization and assembled it into a highly parallel structure.

The major production constraint of cell weeding was eliminated by developing a proprietary culture system that a) used standard single-cell splitting techniques to eliminate the need for periodic weeding, and b) added small molecules to the cell cultures to promote survival and proliferation

Scalability was incorporated into the process by building the cell culture system in a highly parallel nature that enabled the production of billions of iPSCs through the use of CellSTACK culture chambers (Corning, Lowell, MA) rather than standard tissue culture or T-flasks. The large surface area to footprint ratio of the CellSTACK system enabled parallel culturing of iPSCs and resulted in a significant expansion in iPSC production. Currently, this "industrialized" process can generate 100 billion or more iPSCs per month with a small team of manufacturing technicians. Because manufacturing is standardized, production levels can be increased through the addition of additional cell-culture manufacturing lines.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
20%
Attracting a skilled workforce
28%
Obtaining/maintaining adequate financing
12%
Regulatory compliance
40%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here